Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vaxcyte Inc (NQ: PCVX )

106.67 +3.97 (+3.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vaxcyte Inc

< Previous 1 2 3 Next >
Peering Into Vaxcyte's Recent Short Interest
Via Benzinga
Why Recursion Pharmaceuticals Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Peering Into Vaxcyte's Recent Short Interest
Via Benzinga
PCVX Stock Earnings: Vaxcyte Beats EPS for Q1 2024
PCVX stock results show that Vaxcyte beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Recap: Vaxcyte Q4 Earnings
Via Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's... 
Via Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market. 
Via Investor's Business Daily
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the... 
Via Benzinga
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Earnings Scheduled For February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
Preview: Vaxcyte's Earnings
Via Benzinga
Expert Ratings for Vaxcyte
Via Benzinga
Why Shares of Vaxcyte Rose 110.7% This Week
The company released early data for a promising pneumonia vaccine. 
Via The Motley Fool
"Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),  
Via Benzinga
Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst
Mizuho Securities initiated coverage on Vaxcyte Inc (NASDAQ: PCVX), a vaccine company targeting bacterial infectious diseases (primarily for disease prevention).  
Via Benzinga
Where Is The Current Bull Market? Scan Of Stocks Gaining Over 20% Over The Past Week Almost Exclusively Yields Biotech Names
Where is the current bull market? All indications would be that it's in biotech! The broader market is not really moving. There have been plenty of attention-grabbing headlines, and earnings season is... 
Via Benzinga
Why Vaxcyte Stock Is Sliding After Hours
Vaxcyte Inc (NASDAQ: PCVX) shares are trading lower in Monday's after-hours session after the vaccine company announced the commencement of a 
Via Benzinga
This Pneumococcal Vaccine Player Is The Top Pick For 2023 For This Analyst
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2023
Via Benzinga
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market... 
Via Benzinga
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. 
Via Benzinga
Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Earnings Scheduled For February 27, 2023
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.14 per share on revenue of $505.61 million. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 16, 2022
Via Benzinga
Avis Budget, Scholastic And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones gaining over 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 15, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Dow Rises 1.5%; Nasdaq Jumps Over 100 Points
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 450 points on Monday. 
Via Benzinga
Why Tricida Shares Dipped Around 95%; Here Are 73 Biggest Movers From Yesterday
Gainers Applied Genetic Technologies Corporation (NASDAQ: AGTC) climbed 62.4% to close at $0.39. Syncona disclosed that it will acquire Applied Genetic Technologies Corporation. 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.